Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Sintilimab Versus Observation in High-Risk Resected NSCLC
NCT07748325Phase 2Recruiting
- Sponsor
- Sichuan University
- Start
- Jan 2025
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Adjuvant Sintilimab with Observation (2 arms). Primary endpoint: 18-Month Disease-Free Survival Rate. Started Jan 2025; status: recruiting.
02
Drugs
sintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07748325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07748325.